Phortress

Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1[1][2].

Product Specifications

CAS Number

[328087-38-3]

Product Name Alternative

NSC 710305

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/phortress.html

Purity

98.19

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(C2=NC3=CC(F)=CC=C3S2)C=C1C)[C@@H](N)CCCCN.[H]Cl.[H]Cl

Molecular Formula

C20H25Cl2FN4OS

Molecular Weight

459.41

Precautions

H302, H315, H319

References & Citations

[1]Bradshaw TD, et al. In vitro evaluation of amino acid prodrugs of novel antitumour 2- (4-amino-3-methylphenyl) benzothiazoles. Br J Cancer. 2002 Apr 22;86 (8) :1348-54.|[2]Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem. 2004 Apr;11 (8) :1009-21.